MannKind Corporation

NasdaqGM:MNKD 株式レポート

時価総額:US$1.9b

MannKind バランスシートの健全性

財務の健全性 基準チェック /06

MannKindの総株主資本は$-209.9M 、総負債は$227.9Mで、負債比率は-108.6%となります。総資産と総負債はそれぞれ$464.2Mと$674.1Mです。 MannKindの EBIT は$57.3Mで、利息カバレッジ比率2.4です。現金および短期投資は$257.5Mです。

主要情報

-108.6%

負債資本比率

US$227.94m

負債

インタレスト・カバレッジ・レシオ2.4x
現金US$257.49m
エクイティ-US$209.93m
負債合計US$674.13m
総資産US$464.20m

財務の健全性に関する最新情報

更新なし

Recent updates

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Oct 03

MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

MannKind Outperforms As Tyvaso DPI Captures Market Share

May 15

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

Feb 15

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Jan 03
MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

May 15
Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27
MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19
New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14
US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22
Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

MannKind to co-promote Thyquidity

Dec 17

財務状況分析

短期負債: MNKDは マイナスの株主資本 を有しており、これは 短期資産短期負債 をカバーしていないことよりも深刻な状況です。

長期負債: MNKDは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。


デット・ツー・エクイティの歴史と分析

負債レベル: MNKDは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。

負債の削減: MNKDの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。

債務返済能力: MNKDの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 18.2% )。

インタレストカバレッジ: MNKDの負債に対する 利息支払いEBIT ( 2.4 x coverage) によって 十分にカバーされていません


貸借対照表


健全な企業の発掘